Evidence map›Paper›PMID 26457058›Full record

ReviewRisk management and healthcare policy2015

Regulation in the face of uncertainty: the evidence on electronic nicotine delivery systems (e-cigarettes).

Konstantinos E Farsalinos, Jacques Le Houezec

Open access · goldAbstract readReview
In one paragraph

Review in Risk management and healthcare policy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Overview of Electronic Nicotine Delivery Systems: A Systematic Review.American journal of preventive medicine · 2017
    Pooled it
  2. Trial
  3. Second Generation Electronic Nicotine Delivery System Vape Pen Exposure Generalizes as a Smoking Cue.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Does smoking affect your skin?Postepy dermatologii i alergologii · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. E-cigarette Use Related to Demographic Factors in Hawai'i.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2016
    Article
  16. Article
  17. Article
  18. Frontal Cortex Transcriptome Analysis of Mice Exposed to Electronic Cigarettes During Early Life Stages.International journal of environmental research and public health · 2016
    Article
  19. Article
  20. Psoriasis and smoking: links and risks.Psoriasis (Auckland, N.Z.) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 3 countries.

Konstantinos E FarsalinosDepartment of Cardiology, Onassis Cardiac Surgery Center, Kallithea, Greece ; Department of Pharmacy, University of Patras, Patras, Greece.
Jacques Le HouezecDivision of Epidemiology and Public Health, UK Centre for Tobacco and Alcohol Studies, University of Nottingham, Nottingham, England, UK ; Addiction Research Unit, INSERM 1178 (Mental and Public Health), Paris, France.
Inserm · FROnassis Cardiac Surgery Center · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco smoking is the largest single preventable cause of many chronic diseases and death. Effective treatments exist; however, few smokers use them and most try to quit by themselves. Most of the tobacco cigarette's toxicity is related to the combustion process. Models of harm reduction applied to tobacco suggest that switching from inhalation of combustible products to a noncombustible nicotine delivery product would likely result in a vast reduction in tobacco-related death and illness. Currently available evidence raises no doubt that electronic cigarettes (e-cigs) are by far less harmful than smoking (although probably not absolutely safe) and have the potential to be the most effective tobacco harm reduction products due to their unique property of resembling smoking and providing satisfaction to the user. A lot of controversy is surrounding e-cigs and their regulation, much of which is based on the precautionary principle. Although monitoring and further research is definitely needed, the arguments used to implement severe restrictions or bans are mostly hypothetical, weakly supported by evidence, and, in some cases, derived from mispresentation or misinterpretation of the study findings. Regulators should keep in mind that the target population is smokers who want to reduce or quit their deadly tobacco consumption. To achieve this goal, smokers should be honestly informed on the relative harmfulness of the different products. E-cigs are not tobacco products and are not used as medications. For this reason, a specific regulatory scheme is needed, separate from tobacco or medicinal products regulation. Regulation should implement specific quality criteria for products, rules for the exclusion of chemicals of reasonable concern, and appropriate testing for possible contaminants. Additionally, manufacturing standards derived from the food industry should be implemented and adjusted for specific conditions related to e-cigs. Finding the appropriate balance between safety and acceptability of use by smokers will be important in achieving the maximum public health benefit. Labeling should be specified, with warnings about exposure to skin or through ingestion and discouragement of use by nonsmokers, related to the presence of nicotine. Finally, advertising and marketing should not be banned, but appropriately regulated in order to encourage use by the intended population while avoiding use by never-smokers. E-cigs should be appealing to smokers (but not to nonsmokers), while availability and pricing should be strong competitive advantages of e-cigs relative to tobacco cigarettes.

Indexed as

electronic cigarettesnicotineprecautionary principleregulationsmokingtobacco harm reduction

Identifiers

PMID26457058
PMCPMC4598199
OpenAlexW2142066499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.